HC Wainwright & Co. reiterated coverage on BioXcel Therapeutics with a new price target

6/28/21 6:10:49 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

HC Wainwright & Co. reiterated coverage of BioXcel Therapeutics with a rating of Buy and set a new price target of $140.00 from $176.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BTAI

Date	Price Target	Rating	Analyst
2/21/2024	$9.00 → $4.00	Buy → Neutral	UBS
8/15/2023	$40.00 → $4.00	Buy → Neutral	Mizuho
7/17/2023		Buy → Neutral	Guggenheim
3/10/2023	$20.00 → $22.00	Buy → Hold	Jefferies
12/1/2022	$16.00	Sell → Neutral	Goldman
7/7/2022	$19.00	Buy	Mizuho
4/6/2022	$80.00	Buy	BofA Securities
2/16/2022	$88.00 → $25.00	Buy	UBS